Simply Mixing a Cell-Penetrating Peptide with Gene Therapy Viruses Boosts Their Delivery Into Hard-to-Reach Cells | Research

The takeaway

Co-administration of the cell-penetrating peptide Transportan with AAV and lentivirus vectors improved gene delivery efficiency in multiple cell types, including difficult-to-transfect macrophages and retinal cells, with limited toxicity.

Simple co-incubation enhances delivery
Just mixing Transportan peptide with viral vectors before adding them to cells improved gene delivery across multiple cell types — no equipment, chemical modification, or complex protocols required.

What the researchers found

Co-administration of Transportan (TP) with GFP-expressing AAVs and lentivirus enhanced transfection efficiency across multiple cell types with limited cytotoxicity. The approach worked in standard cell lines and, importantly, in difficult-to-transfect cells: the RAW264.7 macrophage cell line, bone marrow-derived macrophages (BMDMs), and retinal pigment epithelium (RPE) cells. The method requires only simple mixing — no specialized equipment, chemical modifications, or complex protocols.

Why it matters

Gene therapy is limited by how well viral vectors can get into target cells. Many clinically important cell types — immune cells for immunotherapy, retinal cells for eye diseases — are resistant to standard viral delivery. A simple, equipment-free method to boost delivery could accelerate gene therapy research and improve clinical outcomes. The ease of implementation (just mixing) makes it immediately adoptable by any lab.

How the study worked

Researchers used GFP-expressing AAV and lentiviral vectors as reporters. Transportan peptide was simply co-incubated with the viral vectors before adding to cells. Transfection efficiency was measured by GFP expression. Multiple cell lines were tested, including easy-to-transfect lines (for validation) and difficult-to-transfect cells: RAW264.7 macrophage line, primary bone marrow-derived macrophages, and primary retinal pigment epithelium cells. Cytotoxicity was assessed alongside transfection efficiency.

What this study cannot tell us

All experiments were in vitro — in vivo gene delivery involves additional barriers (immune responses, tissue distribution) not captured here. The magnitude of transfection improvement was not quantified in the abstract. The mechanism by which Transportan enhances viral uptake (increased endocytosis? membrane interaction? receptor clustering?) was not fully elucidated. Long-term effects on cell health beyond acute cytotoxicity were not assessed. Whether the approach works with different AAV serotypes and at clinical-scale virus preparations is unknown.

How to read the evidence

This is an in vitro proof-of-concept study demonstrating enhanced viral gene delivery using a cell-penetrating peptide. The approach is validated across multiple cell types including clinically relevant primary cells. However, no in vivo data or quantitative enhancement metrics are provided in the abstract.

When this study was published

Published in 2025, this study offers a timely solution as gene therapy increasingly targets difficult-to-transfect cell types for immunotherapy and retinal disease applications.

The bigger picture

Cell-penetrating peptides have been studied primarily for delivering drugs and nucleic acids directly. Using them to boost viral vector delivery is a clever cross-application of peptide technology. As gene therapy moves toward harder-to-reach cell types (neurons, immune cells, retinal cells), practical methods to enhance delivery become critically important. This approach could be particularly valuable for AAV-based therapies, where high vector doses are needed and expensive.

Questions still open

Does Transportan co-administration improve viral gene delivery in vivo, where tissue barriers and immune responses add complexity?
Could this approach reduce the viral vector dose needed for therapeutic gene expression, lowering both cost and immune risks?
What is the mechanism — does Transportan enhance viral binding, endocytosis, or endosomal escape?

Common questions

How can a peptide improve gene therapy delivery?

Transportan is a cell-penetrating peptide that helps things cross cell membranes. By simply mixing it with gene therapy viruses (AAV or lentivirus) before adding them to cells, the peptide enhances how well the viruses can enter cells and deliver their genetic cargo. This is especially useful for immune cells and retinal cells that normally resist viral entry.

Why is this approach significant for gene therapy?

Many promising gene therapies fail because the viral vectors can't get into the target cells efficiently. Current solutions require expensive equipment or can damage cells. This approach needs only simple mixing — making it accessible to any lab — and works on the hardest-to-reach cell types, potentially expanding which diseases can be treated with gene therapy.

Read the original research

Improving viral-based gene delivery to mammalian cells through simple co-incubation with transportan peptide in vitro.

Journal of pharmaceutical sciences, 114(9), 103920

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Nianwu; Hu, Xiangxiang; Pang, Hong-Bo. (2025). Improving viral-based gene delivery to mammalian cells through simple co-incubation with transportan peptide in vitro.. Journal of pharmaceutical sciences, 114(9), 103920. https://doi.org/10.1016/j.xphs.2025.103920